Skip to main content
glpverdict
Editorial medical reviewFDA & peer-reviewed sourcesUpdated weeklyMedically reviewed content
HomeCompareWegovy HD vs Zepbound

Medication comparison

Wegovy HD vs Zepbound

Wegovy HD and Zepbound are both prescription medications (GLP-1 receptor agonist vs GIP/GLP-1 dual receptor agonist) used for Chronic weight management (BMI >=30, or >=27 with at least one weight-related comorbidity) and Chronic weight management. The table below compares FDA-approved indications, dosing, weight-loss outcomes, side effects, contraindications, and current pricing — all sourced from the manufacturer prescribing information.

Find a provider for Wegovy HD or Zepbound

Affiliate disclosure: we earn commission on signups. Editorial ranking stays independent.

This is general drug information, not medical advice. Talk to a licensed clinician before starting, stopping, or switching medication.

Overview

PropertyWegovy HDZepbound
Generic namesemaglutide 7.2 mgtirzepatide
Drug classGLP-1 receptor agonistGIP/GLP-1 dual receptor agonist
ManufacturerNovo NordiskEli Lilly
Brand namesWegovy HDZepbound

Approved uses

PropertyWegovy HDZepbound
Approved indicationsChronic weight management (BMI >=30, or >=27 with at least one weight-related comorbidity)Chronic weight management, Obstructive sleep apnea (adults with obesity)

Dosing

PropertyWegovy HDZepbound
Typical dosingTitrate to 7.2 mg (weekly SC injection)Titrate to 15 mg (weekly SC injection)

Side effects & warnings

PropertyWegovy HDZepbound
Top side effectsNausea (common), Vomiting (common), Diarrhea (common)Nausea (29.6%), Diarrhea (23%), Vomiting (12.6%)
ContraindicationsPersonal or family history of medullary thyroid carcinoma (MTC); Multiple endocrine neoplasia syndrome type 2 (MEN 2); Hypersensitivity to semaglutide or any product component
Boxed warningYesYes

Special populations

PropertyWegovy HDZepbound
PregnancyDiscontinue >=2 months before planned pregnancyC — Discontinue at least 1 month before a planned pregnancy.

Storage

PropertyWegovy HDZepbound
StorageRefrigerate 2-8 C unopened. After first use: room temp up to 28 days.Refrigerate before first use. After first use, room temperature up to 21 days.

Cost

PropertyWegovy HDZepbound
Avg monthly cost$1349.00$1059.87

FDA boxed warning

Wegovy HD: Not established in humans, rodent C-cell tumor signal only; human relevance unknown per FDA label. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.

Zepbound: Risk of thyroid C-cell tumors. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Frequently asked

What is the difference between Wegovy HD and Zepbound?

Wegovy HD is semaglutide 7.2 mg (GLP-1 receptor agonist) and Zepbound is tirzepatide (GIP/GLP-1 dual receptor agonist). They have different active ingredients and slightly different side-effect profiles.

Is Wegovy HD or Zepbound more effective for weight loss?

Head-to-head trial data favors tirzepatide-based medications (Mounjaro, Zepbound) over semaglutide-based medications (Ozempic, Wegovy) in average percent weight loss. SURMOUNT-1 reported ~20.9% mean weight loss on tirzepatide 15 mg; STEP 1 reported ~14.9% on semaglutide 2.4 mg over comparable timelines.

Can I switch between Wegovy HD and Zepbound?

Switching between GLP-1 medications requires re-titration when crossing active ingredients (semaglutide ↔ tirzepatide). Always coordinate with your prescriber before switching.

Other GLP-1 head-to-head comparisons

More medication context

Tools and guides that pair with this comparison.

Affiliate disclosure: we earn commissions when readers sign up through our links. Editorial ranking is independent.